Title : Novavax
Text : {{coord|39.1371167|-77.2258056|region:US-CA|display=title}}
{{Infobox company
| name             = '''Novavax, Inc.'''
| type             = [[Public company|Public]] 
| traded_as        = {{NASDAQ|NVAX}}<br />[[Russell 2000 Index|Russell 2000 Component]]
| area_served      = Worldwide
| industry         = [[Biotechnology]]
| products         = [[Vaccines]] 
| num_employees    = ca 375<ref name=Dive/>
| foundation       = {{Start date and age|1987}} <ref>{{cite web|url=https://www.bloomberg.com/tosv2.html?vid=&uuid=4d473ac0-8537-11e9-bcdf-f180bfa4bf52&url=L3Jlc2VhcmNoL3N0b2Nrcy9wcml2YXRlL3NuYXBzaG90LmFzcD9wcml2Y2FwSWQ9MzUwMzgx|title=Bloomberg - Are you a robot?|website=Bloomberg.com|accessdate=2 June 2019}}</ref>
| location_city    = [[Gaithersburg, Maryland|Gaithersburg]], [[Maryland]]
| location_country = [[United States|U.S.]]
| homepage         = {{URL|http://www.novavax.com/}}
}}

'''Novavax, Inc.''' is a clinical-stage [[vaccine]] company headquartered in [[Gaithersburg, Maryland]] with additional facilities in [[Rockville, Maryland]] and [[Uppsala|Uppsala, Sweden]].  Novavax is a [[public company]] that trades under the symbol "NVAX".<ref>{{cite web|title=Novavax, Inc. News Headlines|url=http://www.nasdaq.com/symbol/nvax/news-headlines|website=NASDAQ|accessdate=8 September 2016}}</ref>

In June 2013, Novavax acquired the Matrix-M<sup>TM</sup> [[adjuvant]] platform with the purchase of Swedish company Isconova AB and renamed it Novavax AB.<ref>{{cite news|last1=Taylor|first1=Nick Paul|title=Novavax makes $30M bid for adjuvant business|url=http://www.fiercepharma.com/vaccines/novavax-makes-30m-bid-for-adjuvant-business|accessdate=9 September 2016|work=FiercePharma|date=3 June 2013}}</ref>

In 2015 the company received an $89 million grant from the [[Bill & Melinda Gates Foundation]] to support the development of a vaccine against [[human respiratory syncytial virus]] for infants via [[Passive immunity|maternal immunization]].<ref>{{Cite web|url=http://www.bizjournals.com/washington/blog/2015/09/gaithersburg-biotech-receives-grant-worth-up-to-89.html|title= Gaithersburg Biotech Receives Grant Worth up to $89 million|website=Bizjournals.com|access-date=2017-03-28}}</ref><ref>{{Cite web|url=http://www.fiercebiotech.com/r-d/promising-rsv-data-hand-novavax-wins-89m-gates-grant-for-phiii|title=With promising RSV data in hand, Novavax wins $89M Gates grant for PhIII {{!}} FierceBiotech|website=Fiercebiotech.com|language=en|access-date=2017-03-28}}</ref><ref>{{Cite news|url=https://www.reuters.com/article/us-novavax-study-idUSKCN0RT19V20150929|title=Novavax RSV vaccine found safe for pregnant women, fetus|date=2016-09-29|work=Reuters|access-date=2017-03-28}}</ref><ref>{{Cite news|url=https://www.forbes.com/sites/matthewherper/2015/09/29/gates-foundation-backs-new-shot-to-prevent-babies-from-dying-of-pneumonia/#1a3b1aea78d4|title=Gates Foundation Backs New Shot To Prevent Babies From Dying Of Pneumonia|last=Herper|first=Matthew|work=Forbes|access-date=2017-03-28}}</ref>

In March 2015 the company completed a Phase I trial for its Ebola vaccine candidate.<ref>{{Cite news|url=https://www.reuters.com/article/us-health-ebola-novavax-idUSKCN0PV1V720150721|title=Novavax's Ebola vaccine shows promise in early-stage trial|date=2017-07-21|work=Reuters|access-date=2017-03-28}}</ref>

In September 2016 the company announced that a Phase III trial of its RSV vaccine had failed to meet its endpoints, which caused its share price to fall from $8.34 to $1.40<ref>{{Cite web|url=http://www.fiercebiotech.com/biotech/novavax-craters-after-phase-iii-rsv-f-vaccine-failure-seeks-path-forward|title=Novavax craters after Phase III RSV F vaccine failure; seeks path forward|website=Fiercebiotech.com|language=en|access-date=2017-03-28}}</ref> and led the company to lay off 30% of its employees.<ref name=Dive/>

As of November 2016 its RSV F vaccine candidate was in three clinical trials.<ref name=Dive>{{Cite news|url=http://www.biopharmadive.com/news/Novavax-q3-restructure-RSV/430370/|title=Novavax aims to rebound with restructuring, more trials|work=BioPharma Dive|access-date=2017-03-28|language=en-US}}</ref><ref name=":0">{{Cite web|url=http://www.fiercepharma.com/vaccines/novavax-hopes-to-revive-rsv-vax-a-new-phase-2-trial|title=Novavax hopes to revive RSV vaccine with a new phase 2 trial|website=Fiercepharma.com|language=en|access-date=2017-03-28}}</ref><ref>{{Cite web|url=http://www.bizjournals.com/washington/news/2017/01/19/novavax-starts-new-clinical-trial-in-bid-to-prove.html|title=Novavax Starts New Clinical Trial in Bid to Prove|website=Bizjournals.com|access-date=2017-03-28}}</ref><ref>{{Cite web|url=http://www.fiercepharma.com/r-d/novavax-takes-rsv-vaccine-into-phase-iii-ahead-of-schedule|title=Novavax takes RSV vaccine into Phase III ahead of schedule {{!}} FiercePharma|website=Fiercepharma.com|language=en|access-date=2017-03-28}}</ref>

==References==
{{Reflist}}

==External links==
*[http://www.novavax.com/ Official website]

{{Finance links|name=Novavax, Inc.|symbol=NVAX|sec_cik=1000694|hoovers=}}
{{Pharmaceutical companies of the United States}}

[[Category:Pharmaceutical companies of the United States]]
[[Category:Companies established in 1987]]
[[Category:Companies based in Gaithersburg, Maryland]]
[[Category:Health care companies based in Maryland]]
